{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:43Z","timestamp":1792218343746,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00520-022-07103-5","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T02:02:31Z","timestamp":1656036151000},"page":"7067-7077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-0265","authenticated-orcid":false,"given":"Hartmut","family":"Link","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"issue":"5","key":"7103_CR1","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1073\/pnas.82.5.1526","volume":"82","author":"K Welte","year":"1985","unstructured":"Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R et al (1985) Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci 82(5):1526\u20131530. https:\/\/doi.org\/10.1073\/pnas.82.5.1526","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"7103_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","volume":"88","author":"K Welte","year":"1996","unstructured":"Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): The first 10 years. Blood 88(6):1907\u20131929","journal-title":"Blood"},{"issue":"6","key":"7103_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.cir-13-0151","volume":"1","author":"D Metcalf","year":"2013","unstructured":"Metcalf D (2013) The colony-stimulating factors and cancer. Cancer Immunol Res 1(6):351\u2013356. https:\/\/doi.org\/10.1158\/2326-6066.cir-13-0151","journal-title":"Cancer Immunol Res"},{"issue":"4746","key":"7103_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1126\/science.2420009","volume":"232","author":"LM Souza","year":"1986","unstructured":"Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC et al (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232(4746):61\u201365. https:\/\/doi.org\/10.1126\/science.2420009","journal-title":"Science"},{"issue":"11","key":"7103_CR5","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood.v78.11.2791.2791","volume":"78","author":"GD Demetri","year":"1991","unstructured":"Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78(11):2791\u20132808. https:\/\/doi.org\/10.1182\/blood.v78.11.2791.2791","journal-title":"Blood"},{"issue":"10","key":"7103_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1084\/jem.20160393","volume":"213","author":"B Bajrami","year":"2016","unstructured":"Bajrami B, Zhu H, Kwak HJ, Mondal S, Hou Q, Geng G et al (2016) G-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling. J Exp Med 213(10):1999\u20132018. https:\/\/doi.org\/10.1084\/jem.20160393","journal-title":"J Exp Med"},{"key":"7103_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/blood.V84.6.1737.1737","volume":"84","author":"GJ Lieschke","year":"1994","unstructured":"Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C et al (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737\u20131746","journal-title":"Blood"},{"key":"7103_CR8","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1073\/pnas.91.12.5592","volume":"91","author":"E Stanley","year":"1994","unstructured":"Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA et al (1994) Granulocyte\/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91:5592\u20135596","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"7103_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2843","volume":"10","author":"D Metcalf","year":"2010","unstructured":"Metcalf D (2010) The colony-stimulating factors and cancer. Nat Rev Cancer 10(6):425\u2013434. https:\/\/doi.org\/10.1038\/nrc2843","journal-title":"Nat Rev Cancer"},{"key":"7103_CR10","volume-title":"Filgrastim","author":"Ratiograstim Epar Product Information","year":"2021","unstructured":"Ratiograstim Epar Product Information (2021) Filgrastim. European Medicines Agency, London"},{"issue":"4","key":"7103_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00001813-200304000-00002","volume":"14","author":"G Molineux","year":"2003","unstructured":"Molineux G (2003) Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anti-Cancer Drugs 14(4):259\u2013264","journal-title":"Anti-Cancer Drugs"},{"issue":"12","key":"7103_CR12","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1185\/03007995.2014.962131","volume":"30","author":"A Buchner","year":"2014","unstructured":"Buchner A, Lammerich A, Abdolzade-Bavil A, Muller U, Bias P (2014) Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers. Curr Med Res Opin 30(12):2523\u20132533. https:\/\/doi.org\/10.1185\/03007995.2014.962131","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"7103_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1172\/jci15994","volume":"111","author":"J-P L\u00e9vesque","year":"2003","unstructured":"L\u00e9vesque J-P, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ (2003) Disruption of the CXCR4\/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Investig 111(2):187\u2013196. https:\/\/doi.org\/10.1172\/jci15994","journal-title":"J Clin Investig"},{"issue":"8596","key":"7103_CR14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/s0140-6736(88)92012-0","volume":"1","author":"MA Socinski","year":"1988","unstructured":"Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD (1988) Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1(8596):1194\u20131198. https:\/\/doi.org\/10.1016\/s0140-6736(88)92012-0","journal-title":"Lancet"},{"issue":"9","key":"7103_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/s0301-472x(02)00883-4","volume":"30","author":"T Lapidot","year":"2002","unstructured":"Lapidot T, Petit I (2002) Current understanding of stem cell mobilization. Exp Hematol 30(9):973\u2013981. https:\/\/doi.org\/10.1016\/s0301-472x(02)00883-4","journal-title":"Exp Hematol"},{"issue":"16","key":"7103_CR16","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/nejmoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al (2012) Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367(16):1487\u20131496. https:\/\/doi.org\/10.1056\/nejmoa1203517","journal-title":"N Engl J Med"},{"key":"7103_CR17","doi-asserted-by":"crossref","unstructured":"Link H, Arseniev L, B\u00e4hre O, Kadar J, Diedrich H, Poliwoda H (1996) Transplantation of allogeneic CD34+ blood cells. Blood 87(11):4903\u20134909","DOI":"10.1182\/blood.V87.11.4903.bloodjournal87114903"},{"key":"7103_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(96)90536-X","volume":"347","author":"N Schmitz","year":"1996","unstructured":"Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353\u2013357","journal-title":"Lancet"},{"issue":"6","key":"7103_CR19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41409-018-0350-y","volume":"54","author":"S Pahnke","year":"2019","unstructured":"Pahnke S, Egeland T, Halter J, H\u00e4gglund H, Shaw BE, Woolfrey AE et al (2019) Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. Bone Marrow Transplant 54(6):858\u2013866. https:\/\/doi.org\/10.1038\/s41409-018-0350-y","journal-title":"Bone Marrow Transplant"},{"key":"7103_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-030-02278-5_15","volume-title":"The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies","author":"K H\u00fcbel","year":"2019","unstructured":"H\u00fcbel K (2019) Mobilization and Collection of HSC. In: Carreras E, Dufour C, Mohty M, Kr\u00f6ger N (eds) The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Springer, Cham (CH), pp 117\u2013122"},{"issue":"12","key":"7103_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/bmt.2009.75","volume":"43","author":"M Trivedi","year":"2009","unstructured":"Trivedi M, Martinez S, Corringham S, Medley K, Ball ED (2009) Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 43(12):895\u2013908. https:\/\/doi.org\/10.1038\/bmt.2009.75","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"7103_CR22","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/cancers13143439","volume":"13","author":"E-M Klein","year":"2021","unstructured":"Klein E-M, Sauer S, Klein S, Tichy D, Benner A, Bertsch U et al (2021) Antibiotic prophylaxis or granulocyte-colony stimulating factor support in multiple myeloma patients undergoing autologous stem cell transplantation. Cancers 13(14):3439. https:\/\/doi.org\/10.3390\/cancers13143439","journal-title":"Cancers"},{"issue":"28","key":"7103_CR23","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"5","key":"7103_CR24","first-page":"544","volume":"11","author":"AK Gupta","year":"2021","unstructured":"Gupta AK, Meena JP, Haldar P, Tanwar P, Seth R (2021) Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis. Am J Blood Res 11(5):544\u2013563","journal-title":"Am J Blood Res"},{"key":"7103_CR25","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","volume":"318","author":"JL Gabrilove","year":"1988","unstructured":"Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414\u20131422","journal-title":"N Engl J Med"},{"issue":"3","key":"7103_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164\u2013170. https:\/\/doi.org\/10.1056\/NEJM199107183250305","journal-title":"N Engl J Med"},{"issue":"10","key":"7103_CR27","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475\u20132484. https:\/\/doi.org\/10.1093\/annonc\/mdt226","journal-title":"Ann Oncol"},{"issue":"2","key":"7103_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23(2):525\u2013545. https:\/\/doi.org\/10.1007\/s00520-014-2457-z","journal-title":"Support Care Cancer"},{"issue":"9","key":"7103_CR29","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","volume":"29","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Yau L, Nakov R, Krendyukov A (2018) Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol 29(9):1903\u20131910. https:\/\/doi.org\/10.1093\/annonc\/mdy311","journal-title":"Ann Oncol"},{"issue":"17","key":"7103_CR30","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/jco.2009.25.8723","volume":"28","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM et al (2010) Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28(17):2914\u20132924. https:\/\/doi.org\/10.1200\/jco.2009.25.8723","journal-title":"J Clin Oncol"},{"key":"7103_CR31","unstructured":"Griffiths EA (2021) NCCN Guidelines Version 3.2021, Hematopoietic growth factors. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)"},{"issue":"3","key":"7103_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"7103_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"4","key":"7103_CR34","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00520-018-4481-x","volume":"27","author":"H Link","year":"2019","unstructured":"Link H, Kerkmann M, Holtmann L, Ortner P (2019) Working Groups Supportive C, Medical Oncology within the German Cancer S. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer 27(4):1459\u20131469. https:\/\/doi.org\/10.1007\/s00520-018-4481-x","journal-title":"Support Care Cancer"},{"issue":"1","key":"7103_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00520-015-2779-5","volume":"24","author":"H Link","year":"2016","unstructured":"Link H, Nietsch J, Kerkmann M, Ortner P (2016) Supportive Care Group of the German Cancer S. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany. Support Care Cancer 24(1):367\u2013376. https:\/\/doi.org\/10.1007\/s00520-015-2779-5","journal-title":"Support Care Cancer"},{"issue":"9","key":"7103_CR36","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","volume":"26","author":"CM Nielson","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J (2021) Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. The Oncologist 26(9):e1609\u2013e1e18. https:\/\/doi.org\/10.1002\/onco.13822","journal-title":"The Oncologist"},{"issue":"5","key":"7103_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","volume":"87","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87(5):429\u2013430. https:\/\/doi.org\/10.1007\/s00277-008-0447-2","journal-title":"Ann Hematol"},{"issue":"10179","key":"7103_CR38","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","volume":"393","author":"R Gray","year":"2019","unstructured":"Gray R, Bradley R, Braybrooke J, Liu Z, Peto R, Davies L et al (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet 393(10179):1440\u20131452. https:\/\/doi.org\/10.1016\/S0140-6736(18)33137-4","journal-title":"The Lancet"},{"key":"7103_CR39","doi-asserted-by":"publisher","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.048","volume":"32","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau CM, Mahammedi H, Laguerre B et al (2021) 652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG\/AFU VESPER V05 phase III trial. Ann Oncol 32:S678. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.048","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"7103_CR40","first-page":"3424","volume":"130","author":"GH Lyman","year":"2017","unstructured":"Lyman GH, Yau L, Nakov R, Krendyukov A (2017a) a systematic literature review of overall survival and delivered dose intensity in cancer patients receiving chemotherapy and G-CSF in randomized control trials. Blood 130(Suppl 1):3424","journal-title":"Blood"},{"key":"7103_CR41","unstructured":"ASCO's 2021 top five list in oncology (2021). https:\/\/www.asco.org\/news-initiatives\/current-initiatives\/cancer-care-initiatives\/value-cancer-care\/choosing-wisely. Accessed 20.12.2021"},{"issue":"1","key":"7103_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00520-017-3854-x","volume":"26","author":"DC Dale","year":"2018","unstructured":"Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E et al (2018) A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 26(1):7\u201320. https:\/\/doi.org\/10.1007\/s00520-017-3854-x","journal-title":"Support Care Cancer"},{"issue":"4","key":"7103_CR43","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2000.18.4.780","volume":"18","author":"JL Harousseau","year":"2000","unstructured":"Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M et al (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18(4):780\u2013787","journal-title":"J Clin Oncol"},{"issue":"10, Suppl. 1","key":"7103_CR44","first-page":"666a","volume":"88","author":"H Link","year":"1996","unstructured":"Link H, Wandt H, Sch\u00f6nrock-Nabulsi P, Ehninger G, Franke A, G\u00e4ckle R et al (1996b) G-CSF (Lenograstim) after chemotherapy for acute myeloid leukemia: A placebo controlled trial. Blood 88(10, Suppl. 1):666a","journal-title":"Blood"},{"issue":"13","key":"7103_CR45","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1056\/NEJM199009273231304","volume":"323","author":"R Ohno","year":"1990","unstructured":"Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T et al (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323(13):871\u2013877. https:\/\/doi.org\/10.1056\/NEJM199009273231304","journal-title":"N Engl J Med"},{"issue":"25","key":"7103_CR46","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJM199506223322504","volume":"332","author":"H Dombret","year":"1995","unstructured":"Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332(25):1678\u20131683. https:\/\/doi.org\/10.1056\/NEJM199506223322504","journal-title":"N Engl J Med"},{"key":"7103_CR47","doi-asserted-by":"publisher","unstructured":"Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I et al (2012) Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008238.pub3","DOI":"10.1002\/14651858.CD008238.pub3"},{"issue":"29","key":"7103_CR48","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1200\/jco.20.01739","volume":"39","author":"PM Desai","year":"2021","unstructured":"Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW et al (2021) Open-label phase II prospective, randomized, controlled study of romyelocel-L Myeloid progenitor cells to reduce infection during induction chemotherapy for acute myeloid leukemia. J Clin Oncol 39(29):3261\u20133272. https:\/\/doi.org\/10.1200\/jco.20.01739","journal-title":"J Clin Oncol"},{"issue":"9","key":"7103_CR49","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/10245332.2018.1446811","volume":"23","author":"X Feng","year":"2018","unstructured":"Feng X, Lan H, Ruan Y, Li C (2018) Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis. Hematology 23(9):581\u2013589. https:\/\/doi.org\/10.1080\/10245332.2018.1446811","journal-title":"Hematology"},{"issue":"27","key":"7103_CR50","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/jco.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 31(27):3360\u20133368. https:\/\/doi.org\/10.1200\/jco.2012.47.4874","journal-title":"J Clin Oncol"},{"issue":"5","key":"7103_CR51","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3324\/haematol.2019.222562","volume":"105","author":"A Tichelli","year":"2020","unstructured":"Tichelli A, De Latour RP, Passweg J, Knol-Bout C, Soci\u00e9 G, Marsh J et al (2020) Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a severe aplastic anemia working party. Haematologica 105(5):1223\u20131231. https:\/\/doi.org\/10.3324\/haematol.2019.222562","journal-title":"Haematologica"},{"issue":"16","key":"7103_CR52","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O et al (2017) Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 376(16):1540\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1613878","journal-title":"N Engl J Med"},{"issue":"2","key":"7103_CR53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172(2):187\u2013207. https:\/\/doi.org\/10.1111\/bjh.13853","journal-title":"Br J Haematol"},{"issue":"1","key":"7103_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1667\/rr15363.1","volume":"192","author":"AL DiCarlo","year":"2019","unstructured":"DiCarlo AL, Horta ZP, Aldrich JT, Jakubowski AA, Skinner WK, Case CM Jr (2019) Use of growth factors and other cytokines for treatment of injuries during a radiation public health emergency. Radiat Res 192(1):99\u2013120. https:\/\/doi.org\/10.1667\/rr15363.1","journal-title":"Radiat Res"},{"issue":"9","key":"7103_CR55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1358\/dot.2015.51.9.2386730","volume":"51","author":"AM Farese","year":"2015","unstructured":"Farese AM, MacVittie TJ (2015) Filgrastim for the treatment of hematopoietic acute radiation syndrome. Drugs Today (Barc) 51(9):537\u2013548. https:\/\/doi.org\/10.1358\/dot.2015.51.9.2386730","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"7103_CR56","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1667\/rr13940.1","volume":"183","author":"KG Hankey","year":"2015","unstructured":"Hankey KG, Farese AM, Blaauw EC, Gibbs AM, Smith CP, Katz BP et al (2015) Pegfilgrastim Improves survival of lethally irradiated nonhuman primates. Radiat Res 183(6):643\u2013655. https:\/\/doi.org\/10.1667\/rr13940.1","journal-title":"Radiat Res"},{"key":"7103_CR57","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejca.2020.06.001","volume":"135","author":"R Yarza","year":"2020","unstructured":"Yarza R, Bover M, Paredes D, L\u00f3pez-L\u00f3pez F, Jara-Casas D, Castelo-Loureiro A et al (2020) SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 135:242\u2013250. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.001","journal-title":"Eur J Cancer"},{"key":"7103_CR58","unstructured":"COVID-19 Patient Care Information - Cancer Treatment & Supportive Care (2021). https:\/\/www.asco.org\/covid-resources\/patient-care-info\/cancer-treatment-supportive-care. Accessed 01\/31\/2022 2021"},{"key":"7103_CR59","doi-asserted-by":"publisher","unstructured":"Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P et al (2020) Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J Natl Compr Canc Netw 1-4. https:\/\/doi.org\/10.6004\/jnccn.2020.7610","DOI":"10.6004\/jnccn.2020.7610"},{"key":"7103_CR60","doi-asserted-by":"publisher","unstructured":"Aapro M, Lyman GH, Bokemeyer C, Rapoport BL, Mathieson N, Koptelova N et al (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 6(1). https:\/\/doi.org\/10.1016\/j.esmoop.2020.100038","DOI":"10.1016\/j.esmoop.2020.100038"},{"key":"7103_CR61","doi-asserted-by":"publisher","unstructured":"Zhang AW, Morjaria S, Kaltsas A, Hohl TM, Parameswaran R, Patel D et al (2021) The Effect of Neutropenia and Filgrastim (G-CSF) in Cancer Patients With COVID-19 Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America: ciab534. https:\/\/doi.org\/10.1093\/cid\/ciab534","DOI":"10.1093\/cid\/ciab534"},{"key":"7103_CR62","doi-asserted-by":"publisher","unstructured":"Sereno M, Jimenez-Gordo AM, Baena-Espinar J, Aguado C, Mielgo X, Pertejo A et al (2021) A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 optionally treated with Granulocyte-Colony Stimulating Factor (G-CSF): A comparative analysis. Cancers 13(16). https:\/\/doi.org\/10.3390\/cancers13164205","DOI":"10.3390\/cancers13164205"},{"issue":"17","key":"7103_CR63","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.2217\/imt-2021-0219","volume":"13","author":"A Lasagna","year":"2021","unstructured":"Lasagna A, Muzzana M, Pedrazzoli P (2021) Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research. Immunotherapy 13(17):1369\u20131372. https:\/\/doi.org\/10.2217\/imt-2021-0219","journal-title":"Immunotherapy"},{"issue":"2","key":"7103_CR64","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00520-020-05906-y","volume":"29","author":"T Cooksley","year":"2021","unstructured":"Cooksley T, Font C, Scotte F, Escalante C, Johnson L, Anderson R et al (2021) Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer 29(2):1129\u20131138. https:\/\/doi.org\/10.1007\/s00520-020-05906-y","journal-title":"Support Care Cancer"},{"issue":"3","key":"7103_CR65","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40(3):402\u2013407. https:\/\/doi.org\/10.1345\/aph.1G516","journal-title":"Ann Pharmacother"},{"issue":"2","key":"7103_CR66","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y et al (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in us clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25(2):439\u2013447. https:\/\/doi.org\/10.1007\/s00520-016-3421-x","journal-title":"Support Care Cancer"},{"issue":"8","key":"7103_CR67","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00520-017-3703-y","volume":"25","author":"GH Lyman","year":"2017","unstructured":"Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT et al (2017b) The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer 25(8):2619\u20132629. https:\/\/doi.org\/10.1007\/s00520-017-3703-y","journal-title":"Support Care Cancer"},{"key":"7103_CR68","unstructured":"Neulasta -Pegfilgrastim. European Medicines Agency; 2007"},{"key":"7103_CR69","unstructured":"NEULASTA\u00ae (pegfilgrastim) injection. Silver Spring, MD 2099: European Medicines Agency: U.S. Food and Drug Administration"},{"issue":"22","key":"7103_CR70","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","volume":"124","author":"M Weise","year":"2014","unstructured":"Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK (2014) Biosimilars: the science of extrapolation. Blood 124(22):3191\u20133196. https:\/\/doi.org\/10.1182\/blood-2014-06-583617","journal-title":"Blood"},{"key":"7103_CR71","unstructured":"Biosimilars of filgrastim (2021). https:\/\/www.gabionline.net\/biosimilars\/general\/Biosimilars-of-filgrastim. Accessed 20.12.2021 2021"},{"issue":"6","key":"7103_CR72","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s00520-015-3057-2","volume":"24","author":"R Pettengell","year":"2016","unstructured":"Pettengell R, Bias P, Mueller U, Lang N (2016) Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Support Care Cancer. 24(6):2677\u20132684. https:\/\/doi.org\/10.1007\/s00520-015-3057-2","journal-title":"Support Care Cancer"},{"issue":"7","key":"7103_CR73","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/14656566.2021.1873950","volume":"22","author":"M Ghidini","year":"2021","unstructured":"Ghidini M, Indini A, Nigro O, Polito S, Rijavec E, Petrelli F et al (2021) Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. Expert Opin Pharmacother 22(7):857\u2013865. https:\/\/doi.org\/10.1080\/14656566.2021.1873950","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"7103_CR74","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-020-05711-7","volume":"29","author":"H Link","year":"2021","unstructured":"Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Kohler A et al (2021) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer 29(5):2519\u20132527. https:\/\/doi.org\/10.1007\/s00520-020-05711-7","journal-title":"Support Care Cancer"},{"issue":"16","key":"7103_CR75","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","volume":"30","author":"JJ Kirshner","year":"2012","unstructured":"Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C et al (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 30(16):1974\u20131979. https:\/\/doi.org\/10.1200\/JCO.2011.37.8364","journal-title":"J Clin Oncol"},{"issue":"4","key":"7103_CR76","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00520-017-3959-2","volume":"26","author":"JJ Kirshner","year":"2018","unstructured":"Kirshner JJ, McDonald MC, Kruter F, Guinigundo AS, Vanni L, Maxwell CL et al (2018) NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer 26(4):1323\u20131334. https:\/\/doi.org\/10.1007\/s00520-017-3959-2","journal-title":"Support Care Cancer"},{"key":"7103_CR77","doi-asserted-by":"publisher","unstructured":"Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JF, Anson-Cartwright L et al (2017) Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumors. Clin genitourinary cancer. https:\/\/doi.org\/10.1016\/j.clgc.2017.08.012","DOI":"10.1016\/j.clgc.2017.08.012"},{"issue":"7","key":"7103_CR78","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1177\/1078155218804293","volume":"25","author":"M Laprise-Lachance","year":"2019","unstructured":"Laprise-Lachance M, Lemieux P, Gr\u00e9goire JP (2019) Risk of pulmonary toxicity of bleomycin and filgrastim. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 25(7):1638\u20131644. https:\/\/doi.org\/10.1177\/1078155218804293","journal-title":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners"},{"key":"7103_CR79","doi-asserted-by":"publisher","unstructured":"Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Iijima M et al (2022) Analysis of the safety of pegfilgrastim addition in bleomycin, etoposide, and cisplatin treatment patients with germ cell tumors. Front Oncol:11. https:\/\/doi.org\/10.3389\/fonc.2021.770067","DOI":"10.3389\/fonc.2021.770067"},{"issue":"4","key":"7103_CR80","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","volume":"60","author":"MD Andersen","year":"2019","unstructured":"Andersen MD, Kamper P, d\u2019Amore A, Clausen M, Bentzen H, d'Amore F (2019) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. Leuk Lymphoma 60(4):927\u2013933. https:\/\/doi.org\/10.1080\/10428194.2018.1515939","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"7103_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00003495-200262001-00005","volume":"62","author":"GH Lyman","year":"2002","unstructured":"Lyman GH, Kuderer NM (2002) Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 62(Suppl 1):65\u201378","journal-title":"Drugs"},{"key":"7103_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103193","volume":"157","author":"P Lapidari","year":"2021","unstructured":"Lapidari P, Vaz-Luis I, Di Meglio A (2021) Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Crit Rev Oncol Hematol. 157:103193. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103193","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"7103_CR83","first-page":"e343","volume":"22","author":"J Vanderpuye-Orgle","year":"2016","unstructured":"Vanderpuye-Orgle J, Sexton Ward A, Huber C, Kamson C, Jena AB (2016) Estimating the social value of G-CSF therapies in the United States. Am J Manag Care 22(10):e343\u2013e3e9","journal-title":"Am J Manag Care"},{"issue":"7","key":"7103_CR84","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1200\/JCO.1995.13.7.1632","volume":"13","author":"PA Bunn Jr","year":"1995","unstructured":"Bunn PA Jr, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C et al (1995) Chemoradiotherapy with or without granulocyte-macrophage colony- stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13(7):1632\u20131641","journal-title":"J Clin Oncol"},{"issue":"1","key":"7103_CR85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2011.01.020","volume":"74","author":"H Sheikh","year":"2011","unstructured":"Sheikh H, Colaco R, Lorigan P, Blackhall F, Califano R, Ashcroft L et al (2011) Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer 74(1):75\u201379. https:\/\/doi.org\/10.1016\/j.lungcan.2011.01.020","journal-title":"Lung Cancer"},{"key":"7103_CR86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lungcan.2021.01.025","volume":"153","author":"F Gomes","year":"2021","unstructured":"Gomes F, Faivre-Finn C, Mistry H, Bezjak A, Pourel N, Fournel P et al (2021) Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. Lung Cancer 153:165\u2013170. https:\/\/doi.org\/10.1016\/j.lungcan.2021.01.025","journal-title":"Lung Cancer"},{"issue":"1109","key":"7103_CR87","doi-asserted-by":"publisher","first-page":"20190147","DOI":"10.1259\/bjr.20190147","volume":"93","author":"M Benna","year":"2020","unstructured":"Benna M, Guy J-B, Bosacki C, Jmour O, Ben Mrad M, Ogorodniitchouk O et al (2020) Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box? Br J Radiol 93(1109):20190147. https:\/\/doi.org\/10.1259\/bjr.20190147","journal-title":"Br J Radiol"},{"key":"7103_CR88","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"issue":"1","key":"7103_CR89","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s13054-018-2076-z","volume":"22","author":"Q Georges","year":"2018","unstructured":"Georges Q, Azoulay E, Mokart D, Soares M, Jeon K, Oeyen S et al (2018) Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data. Critical Care 22(1):326. https:\/\/doi.org\/10.1186\/s13054-018-2076-z","journal-title":"Critical Care"},{"key":"7103_CR90","doi-asserted-by":"publisher","unstructured":"Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014(10):Cd003039. https:\/\/doi.org\/10.1002\/14651858.CD003039.pub2.","DOI":"10.1002\/14651858.CD003039.pub2"},{"issue":"18","key":"7103_CR91","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OA Clark","year":"2005","unstructured":"Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23(18):4198\u20134214. https:\/\/doi.org\/10.1200\/JCO.2005.05.645","journal-title":"J Clin Oncol"},{"issue":"8","key":"7103_CR92","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/1078-0432.Ccr-15-1421","volume":"22","author":"W Hu","year":"2016","unstructured":"Hu W, Sung T, Jessen BA, Thibault S, Finkelstein MB, Khan NK et al (2016) Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clinical Cancer Research : an official Journal of the American Association for Cancer Research 22(8):2000\u20132008. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1421","journal-title":"Clinical Cancer Research : an official Journal of the American Association for Cancer Research"},{"issue":"9","key":"7103_CR93","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","volume":"22","author":"LM Spring","year":"2017","unstructured":"Spring LM, Zangardi ML, Moy B, Bardia A (2017) Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations. The Oncologist 22(9):1039\u20131048. https:\/\/doi.org\/10.1634\/theoncologist.2017-0142","journal-title":"The Oncologist"},{"issue":"9","key":"7103_CR94","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125(9):1403\u20131410. https:\/\/doi.org\/10.1182\/blood-2014-10-604561","journal-title":"Blood"},{"issue":"4","key":"7103_CR95","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s10637-009-9258-0","volume":"28","author":"R Wesolowski","year":"2010","unstructured":"Wesolowski R, Peereboom D, Weiss P, Elson P, Thomas BG (2010) Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies. Invest New Drugs 28(4):502\u2013508. https:\/\/doi.org\/10.1007\/s10637-009-9258-0","journal-title":"Invest New Drugs"},{"issue":"1","key":"7103_CR96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1023\/a:1005945218155","volume":"49","author":"G Frasci","year":"1998","unstructured":"Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R et al (1998) Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat 49(1):13\u201326. https:\/\/doi.org\/10.1023\/a:1005945218155","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"7103_CR97","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1200\/jco.1999.17.5.1407","volume":"17","author":"GK Ellis","year":"1999","unstructured":"Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB (1999) Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients. J Clin Oncol 17(5):1407. https:\/\/doi.org\/10.1200\/jco.1999.17.5.1407","journal-title":"J Clin Oncol"},{"issue":"2","key":"7103_CR98","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/10428194.2014.915544","volume":"56","author":"HL Sun","year":"2015","unstructured":"Sun HL, Atenafu EG, Yeboah E, Reece DE, Trudel S, Kukreti V et al (2015) Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leuk Lymphoma 56(2):407\u2013414. https:\/\/doi.org\/10.3109\/10428194.2014.915544","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"7103_CR99","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1182\/blood.2019002841","volume":"135","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, Tambaro FP (2020) How I manage CLL with venetoclax-based treatments. Blood. 135(17):1421\u20131427. https:\/\/doi.org\/10.1182\/blood.2019002841","journal-title":"Blood"},{"issue":"23","key":"7103_CR100","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 380(23):2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1815281","journal-title":"N Engl J Med"},{"issue":"7","key":"7103_CR101","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMe2118899","volume":"386","author":"M Roschewski","year":"2021","unstructured":"Roschewski M, Longo DL, Wilson WH (2021) CAR T-cell therapy for large B-cell lymphoma \u2014 who, when, and how? N Engl J Med 386(7):692\u2013696. https:\/\/doi.org\/10.1056\/NEJMe2118899","journal-title":"N Engl J Med"},{"issue":"15","key":"7103_CR102","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ et al (2020) Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv 4(15):3776\u20133787. https:\/\/doi.org\/10.1182\/bloodadvances.2020002509","journal-title":"Blood Adv"},{"issue":"S1","key":"7103_CR103","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jha2.350","volume":"3","author":"A Taneja","year":"2021","unstructured":"Taneja A, CAR-T-OPENIA JT (2021) Chimeric antigen receptor T-cell therapy-associated cytopenias. eJHaem 3(S1):32\u201338. https:\/\/doi.org\/10.1002\/jha2.350","journal-title":"eJHaem"},{"issue":"10","key":"7103_CR104","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J et al (2019) Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54(10):1643\u20131650. https:\/\/doi.org\/10.1038\/s41409-019-0487-3","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"7103_CR105","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","volume":"55","author":"E Galli","year":"2020","unstructured":"Galli E, Allain V, Di Blasi R, Bernard S, Vercellino L, Morin F et al (2020) G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma. Bone Marrow Transplant 55(12):2347\u20132349. https:\/\/doi.org\/10.1038\/s41409-020-01006-x","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"7103_CR106","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C et al (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 33(3):259\u2013275. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.003","journal-title":"Ann Oncol"},{"issue":"5","key":"7103_CR107","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11523-021-00824-3","volume":"16","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C (2021) Risk of infection with immune checkpoint inhibitors: a systematic review and meta-analysis. Targ Oncol 16(5):553\u2013568. https:\/\/doi.org\/10.1007\/s11523-021-00824-3","journal-title":"Targ Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07103-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T10:47:28Z","timestamp":1660733248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07103-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["7103"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07103-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"24 June 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}